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Abstract
Objectives: Numerous medical and surgical therapies have been utilized to treat the symptoms
of trigeminal neuralgia (TN). This retrospective study compares patients undergoing either
microvascular decompression or balloon ablation of the trigeminal ganglion and determines which
produces the best long-term outcomes.
Methods: A 10-year retrospective chart review was performed on patients who underwent
microvascular decompression (MVD) or percutaneous balloon ablation (BA) surgery for TN.
Demographic data, intraoperative variables, length of hospitalization and symptom improvement
were assessed along with complications and recurrences of symptoms after surgery. Appropriate
statistical comparisons were utilized to assess differences between the two surgical techniques.
Results: MVD patients were younger but were otherwise similar to BA patients. Intraoperatively,
twice as many BA patients developed bradycardia compared to MVD patients. 75% of BA patients
with bradycardia had an improvement of symptoms. Hospital stay was shorter in BA patients but
overall improvement of symptoms was better with MVD. Postoperative complication rates were
similar (21% vs 26%) between the BA and MVD groups.
Discussion: MVD produced better overall outcomes compared to BA and may be the procedure
of choice for surgery to treat TN.
Background
Trigeminal Neuralgia (TN) is "a sudden brief, usually uni-
lateral, severe, recurrent pain in the distribution of one or
more branches of the fifth cranial nerve" [1]. This pain is
typically triggered by daily activities such as eating, talk-
ing, or brushing teeth. Frequently patients are asympto-
matic between episodes. Although rare, affecting
approximately 4 per 100,000 persons per year, this severe
chronic pain syndrome can greatly compromise patient
quality of life and disrupt daily functioning [2]. The etiol-
ogy of trigeminal neuralgia in the majority of cases is com-
pression of the nerve root by a blood vessel [3]. Other,
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albeit less common etiologies include demylelinating
processes such as Multiple Sclerosis (MS), posterior fossa
meningiomas or neuromas [3].
Pharmacotherapy is generally the mainstay of treatment
of TN, with carbamezapine affording a satisfactory initial
effect in approximately 70% of patients [3]. Other medi-
cations such as gabapentin, baclofen, oxcarbazepine, and
lamotrigine have also been used as primary treatments or
as adjuvants to carbamazepine as well [3]. However, loss
of pharmacological effect or problems with tolerability of
the medications is experienced in almost half of patients
by 10 years of treatment [3]. Fortunately, if medical treat-
ment fails then surgical options are available.
Minimally invasive percutaneous techniques include radi-
ofrequency rhizotomy, glycerol rhizotomy, and balloon
compression gangliolysis (BA) [4]. More invasive tech-
niques such as posterior fossa exploration for microvascu-
lar decompression or partial trigeminal rhizotomy can
also be performed [5]. Microvascular decompression
(MVD) is currently the only technique which corrects the
hypothesized vascular etiology by repositioning the
impinging vessel, usually the superior cerebellar artery or
the anterior inferior cerebellar artery [6]. Multiple prior
comparisons between ablative procedures and MVD exist
in the literature but no recent analysis has compared BA
and MVD [6-10].
Traditionally, BA is reserved for older patients or patients
who may not be able to endure a craniotomy for MVD.
However, it is often surgeon preference that may influence
what surgical technique the patient will undergo. While
both techniques have unique advantages, these proce-
dures are not without complications or side effects.
Manoru, et al. first described a trigeminal depressor
response (TDR) in which bradycardia occurred as a result
of stimulation of the spinal trigeminal complex in rabbits
[11]. This TDR ensued after low frequency stimulation of
any branch of the trigeminal nerve or entering roots. In
another study, Preul, et al. observed bradycardia in 30%
of rabbits receiving percutaneous balloon compression of
the trigeminal ganglion as well as histopathological
changes indicating cellular injury near the inflated bal-
loon [12]. In humans, Brown and Preul described a simi-
lar depressor response with percutaneous
microcompression of the trigeminal ganglion for the relief
of trigeminal neuralgia [13].
Although other investigators have explored the incidence
of intraoperative bradycardia with various ablative proce-
dures, none have yet addressed the question of whether or
not the occurrence of bradycardia may be used as an indi-
rect indicator of sufficient neuronal injury to predict a suc-
cessful outcome of the ablative procedure [13,14].
This paper compares the degree of pain relief and occur-
rence of complications between MVD and BA. It also
examines the incidence of intraoperative bradycardia, an
indicator of trigeminal stimulation with therapeutic out-
comes and attempts to determine which procedure pro-
duces the best therapeutic benefit for patients with TN.
Methods
After obtaining approval from the institutional review
board to perform a retrospective chart review, records of
patients who had trigeminal neuralgia and underwent
either a microvascular decompression via a lateral skull
base approach or a balloon compression rhizolysis of the
trigeminal ganglion between 1993 and 2003 were
reviewed. 120 patients had a total of 164 surgeries during
the review period. Cases of atypical neuralgia, carcinoma-
tous pain or multiple sclerosis were excluded. All patients
had undergone conservative treatment prior to surgical
intervention.
Patients undergoing percutaneous balloon compression
(84 cases) had general anesthesia with either a tracheal
intubation or placement of laryngeal mask airway.
Patients were placed in a supine position with the neck
and thorax slightly flexed. Using biplane fluoroscopy, a
Trucut liver biopsy needle was inserted into the foramen
ovale. A ventricular stylet was next inserted into the hub
of the needle. The catheter was then pushed up to the
foramen ovale. A number 4 Fogerty catheter was placed
into Meckel's Cave and the balloon inflated with 0.75 cc
of contrast media for 3 minutes. The presence of a pear-
shape was seen when compression of the nerve was
accomplished with the balloon. Reflex bradycardia, tear-
ing of the eye, and a modest hypertension insured proper
placement.
Microvascular decompression (80 cases) was done under
general anesthesia. Invasive blood pressure monitoring
was used in a majority of these cases. The patient's head
was turned contralaterally and a small retrosigmoid crani-
otomy was performed. The trigeminal nerve was exam-
ined microsurgically for vascular compression at or near
its point of entry into the brain stem. Compressive arteries
and veins were repositioned and any other compressive
veins were electrocoagulated or divided. In some patients
a rhizotomy was also performed. These patients had atyp-
ical symptoms which were severe enough to warrant
immediate relief with no response to carbamazepine.
Other criteria for performing a rhizotomy included any
patient who had previous invasive procedures for pain
relief or where actual vascular compressive findings dur-
ing surgery were not severe enough to account for the
patient's symptoms.Head & Face Medicine 2008, 4:11 http://www.head-face-med.com/content/4/1/11
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Demographic data was obtained from the records and the
length of disease recorded. Pain medications and previous
treatments for TN were also recorded. Intraoperative vari-
ables collected include OR surgical times, performance of
surgical rhizotomy, incidence of bradycardia during treat-
ment (defined as a decrease of 10% from baseline) and
hospital length of a stay after the procedure. Postoperative
outcomes including the number of patients with immedi-
ate improvement in symptoms, percent of total cure and
the number with no change in symptoms were also
obtained along with the length of time to follow up and
the number of patients who relapsed. Time to relapse was
recorded, as was the total number of operations per-
formed. Reported complications after surgery were also
compared between the two surgical groups and the inci-
dence of the most frequent complications were compared
between the two surgical populations. In addition, the
incidence of bradycardia was correlated to determine if
any relationship exists between the degree of bradycardia
and improvement of systems. Numeric variables were
examined and compared using two tailed t test analysis
while nonparametric variables were compared by Pearson
Chi Square Analysis with a p < 0.05 considered significant.
All values are expressed as mean ± SEM.
Results
A total of 84 patients were in the BA group, while the MVD
group had 80 patients. All MVDs were performed by one
surgeon (DA), while all BAs were performed by another
surgeon (JS). Patients who underwent MVD were signifi-
cantly younger than BA patients (Table 1). Gender, Amer-
ican Society of Anesthesiologists (ASA) physical status,
and length of treatment for TN was approximately the
same in both groups, and a similar utilization of preoper-
ative medications to control TN symptoms were used
(Table 1). A significantly greater number of patients who
received trigger point injections underwent BA treatment
compared to patients who had MVD (Table 1). Finally,
both groups had a similar incidence of prior surgeries for
correction of TN (Table 1).
As would be expected, MVD OR time was significantly
longer than in the BA group (Table 2). Patients who
underwent additional rhizotomy had OR times similar to
MVD. A significantly greater number of patients devel-
oped bradycardia after BA compared to those who under-
went MVD or MVD with rhizotomy (Table 2). In addition,
significantly more BA patients developed bradycardia that
was severe enough to require treatment.
Length of stay was shorter with percutaneous BA com-
pared with MVD (Table 3). MVD produced a significantly
greater number of patients with an immediate improve-
ment of symptoms, as well as cure rate (defined as com-
plete resolution of symptoms at last documented follow-
up) (Table 3). A smaller number of MVD compared to BA
patients (11% vs 27%) had no improvement after surgery
(Table 3). All patients who developed bradycardia during
BA had an improvement of symptoms. Similar improve-
ments in symptoms were noted in MVD and MVD with
rhizotomy patients who developed bradycardia during
the procedure (Table 3). While the incidence of relapse
after surgery was the same in both groups, the length of
time to relapse was slightly shorter after MVD as com-
pared to BA. However, the requirement for postoperative
Table 1: Demographic Data
BA MVD
Age (years) 66.1 ± 1.5 55.6 ± 1.6 *
Gender (%)
Male 33(39%) 37(46%)
Female 51(61%) 43(54%)
ASA Physical Status (%)
1 81 3
2 69 67
3 20 19
4 21
Disease Length (Years) 7.0 ± 0.8 (0.3 – 40) 5.3 ± 0.7 (0.3 – 32)
Number of Medications **
0 71
1 48 43
2 36 38
3 or > 11 19
Incidence of Pre-operative Trigger Point Injections (%) 13.1 3.8 *
Incidence of prior surgery for TN (%) 26 28
* P < 0.05 compared to BA
All data reported as mean ± SEM, ** Medications use perioperatively include: Carbemazepine, Phenytoin, Baclofen, Neurontin, Depakote) used pre-
operatively (%)Head & Face Medicine 2008, 4:11 http://www.head-face-med.com/content/4/1/11
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pharmacologic therapy to treat TN was significantly
reduced after MVD (Table 3).
There was a difference in the incidence of postoperative
complications (excluding paresthesias) between BA and
MVD (Table 4). The incidence of head/face/neck paresthe-
sias was significantly higher in the MVD group (Table 4).
Of all remaining complications, only hearing loss
occurred with greater frequency in the MVD group com-
pared to those in the BA group (Table 4). The hearing loss
noted after MVD was ipsilateral to the surgical field and
was transient in all affected patients. There was a higher
incidence of CSF leak with MVD but no differences in the
incidence of infection or visual changes between the
groups (Table 4). All of the complications involving sight
were either diplopia or blurred vision which usually
resolved in one or two days.
Discussion
Numerous studies have compared different methods of
treatment for trigeminal neuralgia but few have compared
percutaneous BA of the trigeminal ganglion with posterior
fossa MVD [9,15]. Our study is unique in that it compares
the long-term outcomes of the two procedures done
exclusively by two different surgeons performing the same
procedure over a prolonged time period. While the ration-
ale for the decision to have a patient undergo percutane-
ous BA versus MVD was not always elucidated in the
records, the patient's age may have contributed to the
decision-making process: patients undergoing balloon
compression were significantly older. Finally, patients in
the BA group had their disease for a slightly (although not
significantly) longer period than patients who underwent
MVD. This trend is reported by other studies examining
BA procedures and probably reflects a prejudice toward
offering this minimally invasive procedure to older
patients who typically have more comorbid conditions
than their younger counterparts [9,15,16]. However, our
data indicated that there was no difference in ASA Physical
Status between groups, indicating that co-morbidities
may not have contributed to the decision to undergo BA
versus MVD in our institution.
Patients undergoing BA also underwent a significantly
greater amount of treatments prior to surgery with periph-
eral nerve blocks as compared to patients undergoing
MVD. The 13.1% of our patient population who under-
went prior nerve blocks is very similar to the 14.6 percent
Table 2: Intraoperative Variables and Incidence of Bradycardia
BA MVD MVD with Rhizotomy Combined
Total Operating times (min) 23 ± 2 186 ± 6 * 197 ± 7 * 192 ± 5*
Bradycardia 64/84 (76%) 16/37 (43%) * 15/43 (35%)* 31/80 (39%)
Bradycardia Requiring Treatment 16/84 (19%) 0* 3/43 (7%) 33/80 (4%)*
* P < 0.05 compared to BA group
All data reported as mean ± SEM
Combined = MVD with and without rhizotomy
Bradycardia = 10% or greater decrease in Heart Rate
Table 3: Postoperative Outcomes for Rhizotomy, Balloon Ablation, and MVD
BA MVD Rhizotomy Combined
Hospital Length of Stay (Days) 2.6 ± 0.4 5.7 ± 0.6 * 4.3 ± 0.2 5.0 ± 0.3
Without Complications (Days) 0.5 ± 0.1 4.6 ± 0.6 3.3 ± 0.3
Length of Follow-up (Months) 21.8 ± 3.2 33.4 ± 7.1 21.0 ± 4.9 26.5 ± 42
Incidence of Immediate Improvement in Symptoms 56/78 (72%) 31/34 (91%) * 35/41 (85%) * 66/75 (88%)
Improvement of Symptoms with Bradycardia 75% 87% 80% 84%
Incidence of Total Cure 31/78 (40%) ** 23/34 (68%) 22/41 (54%) ** 45/75 (60%)
Incidence of No Change in Symptoms 21/78 (27%) 2/34 (6%) * 6/41 (15%) * 8/75 (11%)*
Incidence of Requirement for Post-Op Medications to Treat TN 45/77 (58%) ** 8/34 (24%) 21/41 (51%) 29/75 (39%)
Incidence of Post-operative Relapse 8/83 (10%) 4/37 (11%) 4/43 (9%) 8/75 (10%)
Incidence of need to have re- operation 22/78 (28%) 3/34 (9%) * 2/42 (5%) * 5/76 (7%)
Time Until Relapse (Months) 12.1 ± 3.1 10.6 ± 8.5 6.3 ± 1.2 8.4 ± 4.1
Number of Patients Lost to Follow-up (%) 7/82 (9%) 5/37 (14%) 4/43 (9%) 9/80 (11%)
* P < 0.05 compared to BA
** P < 0.05 compared to MVD
All data reported as mean ± SEM
Combined = Microvascular Decompression with or without RhizotomyHead & Face Medicine 2008, 4:11 http://www.head-face-med.com/content/4/1/11
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of patients undergoing nerve blocks reported by Lobato,
et al. and may reflect the reluctance of the treating physi-
cian to bring older patients to the operating room [17].
Operating times were significantly less with BA compared
to microvascular decompression. This was expected since
the percutaneous approach is much less invasive and
requires much less surgical time compared to the retrosig-
moid lateral skull base approach needed for MVD. In a
recent analysis by Chen, et al. comparing the same two
procedures, our average time of 23 minutes was shorter
than their operating time for BA, although the hospital
length of stay was equivalent [18]. As would be expected
for a more invasive surgical procedure, hospital length of
stay was significantly longer in the MVD group.
At the onset of the study, we postulated that the occur-
rence of intraoperative bradycardia may be suggestive of a
favorable outcome in the BA group. The rationale behind
this theory was that adequate compression of the trigemi-
nal ganglion required for BA should elicit intra-operative
bradycardia through stimulation of the ganglion. Lack of
bradycardia may suggest that inadequate ganglion com-
pression occurred with a less than optimal outcome. Our
data support this theory. We found that 75% of patients
who had bradycardia with BA had some improvement in
symptoms. Only 40% of these bradycardic patients had a
complete resolution of symptoms. This suggests that
bradycardia is not an indicator of successful nerve abla-
tion and that destruction of the ganglion, in many cases,
may be incomplete with recurrence of symptoms.
Bradycardia occurred in a majority of the balloon ablation
patients and was twice as prevalent when compared to all
patients who underwent MVD. Other studies have noted
a cardiac depressor response during compression of the
trigeminal ganglion [19,20]. Our study found the inci-
dence of bradycardia to be 76%, a value similar to the
70% incidence found by Brown et al [20]. It is interesting
to note that the study which demonstrated a 20% vagal
response used thermocoagulation while the one where a
70% incidence of bradycardia was observed used micro-
compression. It may be possible that a compression of the
ganglion produces a more severe response than that elic-
ited by thermocoagulation. This response most likely
stimulates the efferent arch of the carotid sinus reflex,
which ends in the dorsal nucleus of the vagus and pro-
duces severe bradycardia or asystole. Finally, one study
reported marked tachycardia during ganglion compres-
sion [21]. Their report, however, noted initial bradycardia
upon entering Meckel's Cave and tachycardia immedi-
ately afterward. The explanation for their conflicting find-
ings was light anesthesia and sympathetic stimulation
producing tachycardia.
Patient outcomes were very similar in our study compared
to reports from the literature [15,18]. MVD showed signif-
icantly better immediate relief and total cure rates com-
pared to BA. The higher success rate for microvascular
decompression may be due to the fact that this procedure
is performed on a discrete lesion or vascular loop which
causes the neuralgia and is removed under direct vision.
BA neurolysis however, destroys the ganglion but does
not affectively remove the cause of the pain. Several stud-
ies evaluating outcomes after BA reported total sustained
relief between 70–80% [18,19,22]. Our study noted
improvements of pain symptoms in 72% of patients, a
number similar to the above referenced studies. Immedi-
ate improvement in pain symptoms after MVD was 88%,
a value very similar to the outcomes reported by other
investigations (82–85%) [23,24]. However, long term fol-
low-up showed a total cure rate (i.e. complete resolution
of symptoms) of only 60% at a mean interval of 26.5
months, which is lower than reported follow-up success
rates of 75% at 1 year, 80% at 38 months, 74% at 5 years,
and 64% at 10 years [23-25]. Patients who received an
additional rhizotomy had a higher cure rate of 68% still
lower than that from other reports. We can offer no rea-
sonable explanation as to why our long-term cure rate is
lower than what is reported in literature, except that our
definition of cure was 100% resolution of symptoms,
Table 4: Post-Operative Complications for Rhizotomy, Balloon Ablation, and MVD
BA MVD Rhizotomy Combined
Overall Complication Rate (%) (including paresthesias) 29/83 (35%) 19/37(50%) * 10/43 (23%) 21/80 (26%)
Head/Face/Neck Paresthesias Rate (%) 17/84 (20%) 13/37 (35%) 23/43 (53%) 36/84 (45%) *
Incidence of CSF Leak (%) 0/84 (0%) ** 2/37 (5%) 0/43 (0%) * 2/80 (3%)
Incidence of Infection (%) 0/84 (0%) 1/37 (3%) 1/43 (2%) 2/80 (3%)
Incidence of Visual Changes (%) 6/84 (7%) 0/37 (0%) 2/43 (5%) 2/80 (3%) *
Incidence of Hearing Changes (%) 2/84 (2%) 6/37 (16%)* 6/43 (14%)* 12/80 (16%) *
* P < 0.05 compared to BA
** P < 0.05 compared to MVD
Combined = Microvascular Decompression with or without RhizotomyHead & Face Medicine 2008, 4:11 http://www.head-face-med.com/content/4/1/11
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whereas other authors may have had a less rigorous defi-
nition of "cure", and hence higher successful outcomes.
The incidence of unchanged symptoms after MVD was
11%. While significantly lower than that of the BA group
(27%), it is higher than the reported 2% incidence of
unchanged symptoms reported by Barker, et al [24]. Other
studies however have reported a 7–8% incidence of no
change in symptoms after surgery, which closely approxi-
mates the incidence in the present study [23,25]. Our
relapse rates, defined as a total recurrence of symptoms,
were 10% for both groups. This is considerably lower than
some studies which reported reoccurrence rates after BA to
be as high as 25–30% but equivocal to other studies
reporting rates between 9–14% [22,26-28]. Recurrence of
TN after MVD has been reported as high as 15.3% in some
studies, whereas other studies show a recurrence rate from
6.5–10.2%, again in agreement with our findings [23,29].
Barker, et al., reported several predictive factors for recur-
rence of TN after MVD, including female sex and a longer
preoperative history of TN [24]. Contrary to these find-
ings, we found no significant difference in mean disease
length of treatment and the population of patients with
total cure versus no cure after MVD. Time until relapse was
not significantly different between the BA and MVD
groups (12.1 vs 8.4 months, n = 8). These findings are
consistent with relapse intervals found for MVD (majority
less than 1 year) [30], and for BA (majority within 2 years)
[28].
MVD has several related morbidities associated with the
procedure. The associated mortality risk is 0.3% with an
incidence of neurologic complications reported at 1.7%
[31]. Paresthesias are a well-known side effect of this sur-
gery and occurred at a rate of 45% with MVD versus 20%
in the BA group. The paresthesia occurrence rate for MVD
range from 0.9–4.8% in some papers and 22–36% in oth-
ers with a higher incidence usually related to concurrence
of rhizotomy at the time of MVD [5,8,16]. Our results sup-
port the findings of others. Facial paresthesias were much
higher in MVD procedures with rhizotomy compared to
MVD alone (53% vs 35%). Facial paresthesias for BA sur-
geries have been reported to be around 15%, a value sim-
ilar to our findings [8]. Hematoma, mechanical
ventilation and facial palsy have also been reported. Other
investigators have noted that the three most common
complications that occur after MVD are cerebellar injury,
CSF leak and hearing loss [24]. None of our patients
developed cerebellar injury but 3% developed a CSF leak
and 15% of patients undergoing MVD were noted to have
hearing loss. No difference was noted in hearing loss if the
procedure was also accompanied by rhizotomy. The hear-
ing loss was transient and the short duration of these
symptoms suggest conductive hearing loss secondary to
fluid in the mastoid air cells after surgery and not direct
trauma to the nerve. Some studies reported hearing loss to
occur in 24% of all patients while other studies placed
hearing lost between 0.8–7.5%, more consistent with our
findings [24,29]. Hearing complications may also occur
from cerebellar retraction and many have suggested that if
cerebellar retraction is necessary, the duration should be
brief. The direction of the traction applied should also be
perpendicular to the axis of cranial nerve VIII [24]. The
surgeon who performed the MVD (DA) did not use cere-
bellar retraction for these procedures, thus direct trauma
to the nerve producing hearing loss was unlikely.
Our study is in agreement with previous comparisons of
MVD and trigeminal ganglion BA which show that MVD
provides better outcomes with more sustained pain relief
and a lower incidence of recurrence [6,10]. The reduced
use of medication postoperatively and the lower number
of patients that reported no improvement in symptoms
after surgery points to the fact that MVD produces a better
outcome compared to BA procedures.
Furthermore, our data suggests that a history of prior sur-
geries for correction of TN is a negative prognostic factor
for outcomes with BA surgeries. Even though MVD is
more invasive and requires longer hospitalizations, the
long-term outcomes favor this procedure.
Conclusion
In conclusion, we believe that MVD is the best procedure
to reduce and eliminate the symptoms of trigeminal neu-
ralgia and recommend this procedure over BA rhizolysis,
even in older patients, if their physical status allows them
to tolerate a posterior fossa craniotomy.
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